Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ADMA, EOLS, TELA, GLPG, ZVRA, and represent 42.65% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: OPTN, TELA, IKT, INO, ENTA, CALC, PROF, VIR, ANIP, MYO.
- Started 22 new stock positions in XERS, AMRN, VIR, SLRN, HLVX, ANIP, KZR, CALC, CHRS, ALLR. ELEV, PMVP, PROF, OPTN, ENTA, AQST, ANTX, ABVX, INO, HRTX, IKT, VNDA.
- Reduced shares in these 10 stocks: ADMA (-$11M), GLPG (-$7.7M), RPRX (-$6.0M), JAZZ (-$5.5M), RIGL (-$5.0M), ACRS, Optinose, Revance Therapeutics, VSTM, XOMA.
- Sold out of its positions in ARQT, Kezar Life Sciences, Optinose, FNA, RIGL, TENX, VIRX, RPRX.
- Stonepine Capital Management was a net seller of stock by $-28M.
- Stonepine Capital Management has $124M in assets under management (AUM), dropping by -21.71%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 52 positions in its portfolio as reported in the December 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
|---|---|---|---|---|---|---|
| Adma Biologics (ADMA) | 17.2 | $21M | -33% | 1.2M | 17.15 |
|
| Evolus (EOLS) | 11.3 | $14M | -7% | 1.3M | 11.04 |
|
| Tela Bio (TELA) | 5.7 | $7.1M | +111% | 2.4M | 3.02 |
|
| Galapagos Nv- Spon Adr (GLPG) | 4.4 | $5.5M | -58% | 200k | 27.50 |
|
| Zevra Therapeutics Com New (ZVRA) | 4.0 | $5.0M | -14% | 598k | 8.34 |
|
| Verastem Com New (VSTM) | 3.6 | $4.5M | -33% | 870k | 5.17 |
|
| ACADIA Pharmaceuticals (ACAD) | 3.3 | $4.0M | +11% | 220k | 18.35 |
|
| Optinose Com New (OPTN) | 3.2 | $3.9M | NEW | 589k | 6.68 |
|
| Anika Therapeutics (ANIK) | 3.2 | $3.9M | +25% | 238k | 16.46 |
|
| Indivior Ord (INDV) | 3.1 | $3.8M | +12% | 305k | 12.43 |
|
| Establishment Labs Holdings Ord (ESTA) | 3.0 | $3.7M | +6% | 80k | 46.07 |
|
| Inhibikase Therapeutics Com New (IKT) | 3.0 | $3.7M | NEW | 1.1M | 3.25 |
|
| Urogen Pharma (URGN) | 2.8 | $3.5M | +15% | 324k | 10.65 |
|
| Xoma Corp Com New (XOMA) | 2.7 | $3.3M | -35% | 126k | 26.28 |
|
| Day One Biopharmaceuticals I (DAWN) | 2.4 | $3.0M | +14% | 235k | 12.67 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 2.3 | $2.9M | -35% | 649k | 4.43 |
|
| Scpharmaceuticals (SCPH) | 2.0 | $2.4M | -12% | 684k | 3.54 |
|
| Surrozen Com New (SRZN) | 1.6 | $2.0M | +24% | 137k | 14.35 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 1.6 | $1.9M | NEW | 1.1M | 1.83 |
|
| Enanta Pharmaceuticals (ENTA) | 1.5 | $1.9M | NEW | 332k | 5.75 |
|
| Myomo Com New (MYO) | 1.4 | $1.8M | +174% | 274k | 6.44 |
|
| Calcimedica Com New (CALC) | 1.3 | $1.7M | NEW | 469k | 3.54 |
|
| Aclaris Therapeutics (ACRS) | 1.3 | $1.6M | -73% | 663k | 2.48 |
|
| Profound Medical Corp Com New (PROF) | 1.2 | $1.5M | NEW | 200k | 7.51 |
|
| Jazz Pharmaceuticals Plc Us Listed Shs Usd (JAZZ) | 1.0 | $1.2M | -81% | 10k | 123.15 |
|
| Vir Biotechnology (VIR) | 1.0 | $1.2M | NEW | 164k | 7.34 |
|
| Milestone Pharmaceuticals In Com New (MIST) | 1.0 | $1.2M | -49% | 500k | 2.36 |
|
| Biosante Pharmaceuticals (ANIP) | 0.9 | $1.1M | NEW | 20k | 55.28 |
|
| Heron Therapeutics (HRTX) | 0.9 | $1.1M | NEW | 700k | 1.53 |
|
| Exagen (XGN) | 0.8 | $1.0M | -53% | 251k | 4.10 |
|
| 2seventy Bio Common Stock (TSVT) | 0.7 | $882k | +200% | 300k | 2.94 |
|
| Iteos Therapeutics (ITOS) | 0.7 | $845k | +266% | 110k | 7.68 |
|
| Pmv Pharmaceuticals (PMVP) | 0.7 | $809k | NEW | 536k | 1.51 |
|
| Kezar Life Sciences (KZR) | 0.6 | $739k | NEW | 110k | 6.72 |
|
| Aytu Biopharma (AYTU) | 0.6 | $693k | -18% | 408k | 1.70 |
|
| Adicet Bio (ACET) | 0.5 | $673k | +14% | 700k | 0.96 |
|
| Kiora Pharmaceuticals (KPRX) | 0.5 | $663k | 201k | 3.30 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.5 | $618k | NEW | 182k | 3.39 |
|
| Aquestive Therapeutics (AQST) | 0.5 | $570k | NEW | 160k | 3.56 |
|
| Aprea Therapeutics Com New (APRE) | 0.4 | $491k | +8% | 149k | 3.29 |
|
| Acelyrin (SLRN) | 0.3 | $417k | NEW | 133k | 3.14 |
|
| Coherus Biosciences (CHRS) | 0.3 | $345k | NEW | 250k | 1.38 |
|
| Polypid (PYPD) | 0.3 | $315k | -25% | 104k | 3.04 |
|
| Hillevax (HLVX) | 0.2 | $274k | NEW | 132k | 2.07 |
|
| An2 Therapeutics (ANTX) | 0.2 | $272k | NEW | 197k | 1.38 |
|
| Vanda Pharmaceuticals (VNDA) | 0.1 | $120k | NEW | 25k | 4.79 |
|
| Elevation Oncology (ELEV) | 0.1 | $113k | NEW | 200k | 0.56 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.1 | $110k | NEW | 15k | 7.32 |
|
| Alimera Sciences Inc Cvr | 0.1 | $107k | 2.4M | 0.04 |
|
|
| Allarity Therapeutics (ALLR) | 0.1 | $79k | NEW | 67k | 1.17 |
|
| Revance Therapeutics | 0.1 | $71k | -97% | 23k | 3.04 |
|
| Amarin Corporation Plc - Spons Adr New (AMRN) | 0.0 | $55k | NEW | 114k | 0.48 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2024 Q4 filed Feb. 14, 2025
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022
- Stonepine Capital Management 2022 Q2 filed Aug. 12, 2022
- Stonepine Capital Management 2022 Q1 filed May 16, 2022
- Stonepine Capital Management 2021 Q4 filed Feb. 14, 2022
- Stonepine Capital Management 2021 Q3 filed Nov. 12, 2021